Abstracts tagged "myositis and systemic sclerosis"

Abstract Number: 1722 • 2017 ACR/ARHP Annual Meeting
Identification of a Sub-Population of Autoantibodies Targeting BICD2 Cross-Reacting with CENP-a Derived Peptides in Patients with Systemic Sclerosis
Michael Mahler¹, Chelsea Bentow¹, Jay Milo¹, May Choi², Mianbo Wang³, Petra Budde⁴, Murray Baron⁵, Marie Hudson⁶ and Marvin J. Fritzler⁷, ¹Research and Development, Inova Diagnostics, San Diego, CA, ²University of Calgary, Calgary, AB, Canada, ³Lady Davis Institute for Medical Research, Montreal, QC, Canada, ⁴Protagen AG, Dortmund, Germany, ⁵Rheumatology, Jewish General Hospital, Montreal, QC, Canada, ⁶Division of Rheumatology, Jewish General Hospital, Lady David Institute for Medical Research, Montreal, QC, Canada, ⁷Medicine, University of Calgary, Calgary, AB, Canada
Background/Purpose: Anti-nuclear antibodies (ANA) are present in approximately 90% of sera from systemic sclerosis (SSc) patients and play an important role in the diagnosis and…
Abstract Number: 1894 • 2016 ACR/ARHP Annual Meeting
Increased Mortality in Systemic Sclerosis Patients with Fibrosing Myopathy
Julie J. Paik¹, Fredrick M. Wigley², Ami A. Shah¹, Andrea Corse³, Laura K. Hummers⁴ and Andrew Mammen⁵, ¹Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheum Div/Mason F Lord, Johns Hopkins University School of Medicine, Baltimore, MD, ³Neurology, Johns Hopkins University, Baltimore, MD, ⁴Johns Hopkins University School of Medicine, Baltimore, MD, ⁵National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: Skeletal myopathy in systemic sclerosis (SSc) is associated with poor outcomes such as disability. The spectrum of muscle histopathology of weak SSc patients is…
Abstract Number: 2374 • 2015 ACR/ARHP Annual Meeting
Pulmonary Arterial Hypertension in Patients with Anti-PM-Scl Antibody
Hiromichi Tamaki¹, Ruchi Yadav², James Bena³ and Soumya Chatterjee⁴, ¹Department of Rheumatic and Immunologic Diseases, Cleveland Clinic Foundation, Cleveland, OH, ²Diagnostic Radiology, Cleveland Clinic, Cleveland, OH, ³Department of Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, OH, ⁴Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Pulmonary arterial hypertension (PAH) may be a disease manifestation of patients with anti-PM-Scl antibody (PM-Scl). In the 2014 ACR annual meeting we reported significantly…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].